McKesson Corporation vs Nutrien Ltd — how do they compare? McKesson Corporation trades at $884.91 (market cap $105.14B), while Nutrien Ltd trades at $65.9 (market cap $32.05B). The key difference: McKesson Corporation is far larger — about 3.3× Nutrien Ltd's market cap, and Nutrien Ltd pays the higher dividend (3.27%). Which is the better fit depends on your goals.
| MCK | NTR | |
|---|---|---|
Market Cap | $105.14B | $32.05B |
Sector | Health | Basic Materials |
52-Week High | $995.69 | $83.94 |
52-Week Low | $659.01 | $53.64 |
Enterprise Value | $111.67B | $43.86B |
Dividend Yield | 0.42% | 3.27% |
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.
The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.
Nutrien (NTR) trades at $66.43, up 0.18% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings, missing EPS estimates but beating revenue expectations, driven by higher potash prices. Financials show a net income margin of 8.44% for 2025, with a P/E ratio of 13.62 indicating reasonable valuation. Recent news highlights institutional buying and dividend declarations, while cash flow trends indicate consistent operational strength amid net outflows.
Outlook remains cautiously optimistic with a consensus price target of $76.17, suggesting 14.6% upside, supported by analyst buy ratings at 60.6%. Key opportunities include structural gas arbitrage benefits and agricultural cycle recovery, but risks involve input cost pressures, volatile fertilizer demand, and earnings consistency challenges. The stock presents a value opportunity with dividend yield, though macroeconomic and sector-specific headwinds warrant monitoring.
Trailing returns across standard periods
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →